David Oubre, MD
Hematology & Oncology · Hammond, LANPI 1104883305
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (36.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 22.1%. Reporting peaked in 2020 at $31,418 and has fallen 76.2% since, to $7,477 in 2025. Among hematology & oncology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,142 payments — averaging $70.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$18K
- Daiichi Sankyo Inc.$13K
- Sobi, Inc$7K
- AstraZeneca$5K
- Gilead$5K
- Rigel Pharmaceuticals, Inc.$5K
- plus $28K from 54 others
Across 282 payments — averaging $4858.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Helsinn Healthcare SA$386K
- AstraZeneca$149K
- Beigene USA, Inc.$87K
- Eli Lilly$80K
- Genentech, Inc.$72K
- Mirati Therapeutics, Inc.$71K
- plus $526K from 16 others
What the payments were for
- Consulting fees$25,79932%
- Speaking & faculty fees$29,14836%
- Travel & lodging$2,2733%
- Food & beverage$23,21729%
- Education$5911%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$81,027 in reported general payments places this provider in the 90th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 51 | $788,002 |
| IbrancePalbociclib | 43 | $675,955 |
| Lenalidomide | 51 | $648,129 |
| GivlaariGivosiran Sodium | 13 | $551,603 |
| CalquenceAcalabrutinib Maleate | 34 | $515,157 |
| XtandiEnzalutamide | 29 | $418,509 |
| JakafiRuxolitinib Phosphate | 24 | $405,228 |
| CabometyxCabozantinib S-Malate | 13 | $314,693 |
| LumakrasSotorasib | 12 | $254,669 |
| BrukinsaZanubrutinib | 18 | $254,456 |
| PomalystPomalidomide | 11 | $251,188 |
| NinlaroIxazomib Citrate | 20 | $244,285 |
| KisqaliRibociclib Succinate | 14 | $239,001 |
| RevlimidLenalidomide | 18 | $209,898 |
| StivargaRegorafenib | 11 | $189,527 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $398 | $788,00251 claims |
| PfizerIbrance, Eliquis, Retacrit | $3,149 | $713,719119 claims |
| AstraZenecaCalquence | $5,220 | $515,15734 claims |
| Astellas Pharma US IncXtandi | $607 | $418,50929 claims |
| Incyte CorporationJakafi | $609 | $405,22824 claims |
| Exelixis Inc.Cabometyx | $117 | $314,69313 claims |
| AmgenLumakras, Xgeva | $527 | $292,34024 claims |
| Beigene USA, Inc.Brukinsa | $236 | $254,45618 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $874 | $251,18811 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $2,053 | $244,28520 claims |
| NovartisKisqali | $1,570 | $239,00114 claims |
| Bristol Myers SquibbRevlimid | $976 | $209,89818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in Hammond
- Hana SafahBaton Rouge$2M
- Pedro BarataNew Orleans$928K
- Maissaa JanbainNew Orleans$862K
- Nakhle SabaBaton Rouge$842K
- Marc MatranaNew Orleans$757K
- Prakash PeddiShreveport$405K
- Sanjay JunejaBaton Rouge$346K
- Lingling duNew Orleans$173K
- Kamran ShahidLake Charles$155K
- Kevin GallagherShreveport$145K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.